急性髓系白血病移植后的长期结局
本文为肿瘤学大查房系列文章,以病例展示引出急性髓系白血病(AML)造血干细胞移植(HSCT)后长期并发症的讨论。文中述及异基因HSCT已成为主流巩固治疗,移植策略与支持治疗改善使长期存活者增多;Armenian等在大型队列中分析AML移植后晚期并发症负担,并与同胞比较严重/危及生命情况。研究强调对原发病近乎治愈的移植患者需延长临床随访以监测晚期恶性和非恶性并发症。
要点
- 异基因HSCT是目前AML移植巩固治疗的几乎普遍选择,自体HSCT已几乎从日常实践消失。
- 移植策略改进、支持治疗改善和供者来源增加使HSCT后长期存活者数量增加。
- Armenian等在大型队列中分析AML移植后晚期并发症负担,并与同胞比较严重/危及生命情况。
核心结论
- Armenian等的研究强化了对原发病近乎治愈的移植患者进行延长临床随访、以监测晚期恶性和非恶性并发症的必要性。
研究设计与样本
- 本文为肿瘤学大查房系列文章,包含病例展示、诊断与管理挑战描述、相关文献综述及作者建议的管理方法总结。
- Armenian等在大型队列中分析AML患者HSCT后晚期并发症负担,并将严重/危及生命情况与同胞进行比较。
主要发现
- HSCT作为AML巩固治疗已使用超过四十年,如今几乎普遍使用异基因HSCT,自体HSCT已几乎从日常实践消失。
- 移植策略改进、支持治疗改善及供者来源增加使HSCT后长期存活者数量增加。
- Armenian等分析了大型队列中AML患者HSCT后晚期并发症负担,并将严重/危及生命情况与同胞比较。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.Hematopoietic stem-cell transplantation (HSCT) has been used for more than four decades as consolidation therapy in acute myelogenous leukemia (AML). Allogeneic HSCT is almost universally used today, and autologous HSCT nearly disappeared from daily practice. Improvement in transplantation strategies, supportive care, and increased donor source availability led to increased numbers of long-term survivors after HSCT. In the accompanying paper of this ground rounds, Armenian and coworkers analyzed the burden of late complications after HSCT for AML in a large cohort of patients and compared severe/life-threatening conditions with those of siblings. This study reinforces the need for prolonged clinical follow-up of transplanted patients otherwise nearly cured of their original disease for late malignant and nonmalignant complications.
引用
- Socie G. Long-Term Outcomes After Transplantation for Acute Myelogenous Leukemia. J Clin Oncol. 2022. PMID: 35930761. doi:10.1200/JCO.22.01177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。